Novo Holdings, the controlling shareholder of Novo Nordisk, on Wednesday sealed its $16.5 billion deal for Catalent, as the ...

Novo Holdings has completed its $16.5 billion acquisition of Catalent, the contract drug manufacturer said on Wednesday, days ...

Catalent, Inc. ("Catalent"), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences investment ...

Indications are that Novo will be investing in both the plant and the community,” an Indiana University professor said.

(RTTNews) - Wednesday, Novo Holdings A/S completed the acquisition of Catalent, Inc. (CTLT), a global contract development and manufacturing organization, in an all-cash transaction worth enterprise ...

Indications are that Novo will be investing in both the plant and the community,” an Indiana University professor said.

The U.S. Centers for Disease Control and Prevention said on Wednesday a patient has been hospitalized with a severe case of ...

Healthcare provisions in a stopgap bill unveiled by top Republicans and Democrats are likely manageable for companies that ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Also Read: Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent Benzinga reached out to Novo Nordisk’s media team but has not heard ...

Indeed, there weren’t many more biotech IPOs in 2024 than in 2023, and the companies that did venture out this year struggled ...

Suddenly the hottest thing in biopharma isn’t a new indication, disease target or modality—it’s manufacturing, and all of ...